Clinical Trials Logo

Influenza Prevention clinical trials

View clinical trials related to Influenza Prevention.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06280144 Recruiting - Clinical trials for Influenza Prevention

Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine

Start date: September 22, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine. To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine.

NCT ID: NCT05056519 Recruiting - Clinical trials for Influenza Prevention

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

Start date: September 20, 2021
Phase: Phase 1
Study type: Interventional

Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021. The main objective of phase Ⅰ trail is to evaluate the safety of LAVI(non freeze-dried). The secondary objective is to evaluate the immunogenicity of LAVI(non freeze-dried).